Tags : Investigational

Janssen’s Investigational Prophylactic Vaccine Receives the US FDA’s Breakthrough Therapy

Shots: The US FDA’s breakthrough therapy designation is based on the clinical study assessing prophylactic vaccine in RSV patients aged ≥60yrs. vs SOC demonstrating substantial improvement in the clinically significant endpoints Following BT designation, Janssen’s vaccine is eligible for all associated FDA features and is currently being evaluated in P-IIb proof of concept study evaluating […]Read More